Arcutis Biotherapeutics, Inc.
ARQT • NASDAQ
Arcutis Biotherapeutics, Inc. is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Todd Franklin Watanabe, with a market cap of $2.6B.
CEOTodd Franklin Watanabe
Next Earnings
Upcoming earnings announcement for Arcutis Biotherapeutics, Inc.
Date
Tuesday, May 5, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.03
Revenue Estimate
$102.6M
Earnings History
Past 12 earnings reports for Arcutis Biotherapeutics, Inc.
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 25, 2026 | Q4 2025 | $0.13Est: $0.07 | +85.7% | $129.5MEst: $114.1M | +13.5% |  10-K |
| Oct 28, 2025 | Q3 2025 | $0.06Est: -$0.10 | +160.0% | $99.2MEst: $86.7M | +14.4% | 10-Q |
| Aug 6, 2025 | Q2 2025 | -$0.13Est: -$0.16 | +18.8% | $81.5MEst: $73.2M | +11.3% | 10-Q |
| May 6, 2025 | Q1 2025 | -$0.20Est: -$0.21 | +4.8% | $65.8MEst: $62.5M | +5.4% | 10-Q |
| Feb 25, 2025 | Q4 2024 | -$0.09Est: -$0.27 | +66.7% | $71.4MEst: $57.8M | +23.6% | 10-K |
| Nov 6, 2024 | Q3 2024 | -$0.33Est: -$0.42 | +21.4% | $44.8MEst: $37.6M | +19.0% | 10-Q |
| Aug 14, 2024 | Q2 2024 | -$0.42Est: -$0.57 | +26.3% | $30.9MEst: $27.1M | +13.8% | 10-Q |
| May 14, 2024 | Q1 2024 | -$0.32Est: -$0.73 | +56.2% | $49.6MEst: $14.7M | +237.7% | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$0.72Est: -$0.77 | +6.5% | $13.5MEst: $11.3M | +19.3% | 10-K |
| Nov 3, 2023 | Q3 2023 | -$0.73Est: -$0.86 | +15.1% | $38.1MEst: $32.8M | +16.1% | — |
| Aug 8, 2023 | Q2 2023 | -$1.16Est: -$1.22 | +4.9% | $5.2MEst: $4.9M | +6.6% | — |
| May 9, 2023 | Q1 2023 | -$1.31Est: -$1.28 | -2.3% | $2.8MEst: $3.1M | -11.4% | — |